Lidorestat

Research use only, not for human use.

Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity. Lidorestat improves nerve conduction and reduces the formation of cataracts.

Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.

From in vitro experiments, Lidorestat has a reported IC50 against recombinant human aldose reductase (/h/-ALR2) of 5 μM. Against recombinant human aldehyde reductase (/h/-ALR1), Lidorestat has a reported IC50 of 27,000 μM, yielding a selectivity of /h/-ALR1//h/-ALR2 of 5400:1.

Lidorestat (25 mg/kg/day; oral administration; twice daily; for 6 weeks; diabetic mice) treatment decreases fructose and reduces mortality in diabetic hAR-expressing mice. And Lidorestat does not affect weight.Animal Model:Diabeticlow-density lipoprotein (LDL) receptor-deficient [Ldlr(-/-)] mice Dosage:25 mg/kg/day Administration:Oral administration; twice daily; for 6 weeks Result: Diabetic hAR-expressing mice had decreased fructose and reduced mortality.

——

Endocrinology/Hormones

Reductase

Reductase

——

——

245116-90-9

376.35

C18H11F3N2O2S

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (132.86 mM; Ultrasonic (<60°C)

OC(=O)Cn1cc(Cc2nc3c(F)c(F)cc(F)c3s2)c2ccccc12

——

(-20℃)

With Ice Pack

≥ 2 years